Stonegate Capital Partners has updated its coverage on OS Therapies Inc. (NYSE: OSTX), highlighting significant progress in the company's regulatory and commercialization efforts for its lead candidate OST-HER2. The therapy, aimed at treating recurrent, fully resected, pulmonary metastatic osteosarcoma, has moved from Phase 2b-supported planning toward a more defined global approval pathway, according to the analyst report.
The key development is greater regulatory clarity. The European Medicines Agency (EMA) has initiated a rolling review of the OST-HER2 Conditional Marketing Authorization (CMA) dossier, while the EMA and Australia's Therapeutic Goods Administration (TGA) have aligned on three-year overall survival as the approvable efficacy endpoint. This alignment is crucial for advancing the therapy through regulatory processes in multiple jurisdictions.
Management has also positioned seroconversion biomarker data as supportive surrogate efficacy evidence, shifting the investment debate from early proof-of-concept toward execution across a dense 2026 catalyst calendar. Key milestones include 2.5-year overall survival (OS) data in mid-second quarter 2026, meetings with the U.S. Food and Drug Administration (FDA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in the second quarter of 2026, initiation of a Phase 3 trial in Australia in the third quarter of 2026, three-year OS data in early fourth quarter of 2026, and a potential EMA CMA decision in the fourth quarter of 2026.
According to Stonegate, regulatory clarity is the core value inflection. The EMA rolling review, TGA endpoint alignment, MHRA Advanced Therapy Medicinal Product (ATMP) designation, and upcoming FDA/MHRA meetings shift OST-HER2 from Phase 2b validation toward an executable global approval pathway. Survival data remain the key catalyst stack, with mid-2Q26 2.5-year OS data and early-4Q26 three-year OS data expected to determine whether OS Therapies can complete the EMA CMA submission and sustain accelerated-access momentum.
Financing and Priority Review Voucher (PRV) optionality bridges the regulatory window. The company completed a $5.25 million raise, plus expects $4.0 million in non-dilutive funding, supporting 2026 catalysts. A potential PRV remains a meaningful approval-contingent valuation lever, with the latest public transaction at $205 million, as noted in the report.
The full announcement, including downloadable images and bios, is available here. OS Therapies Inc. (NYSE: OSTX) is focused on developing treatments for osteosarcoma, a rare bone cancer primarily affecting children and young adults.
